Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular...

Descripción completa

Detalles Bibliográficos
Autores principales: Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224042/
https://www.ncbi.nlm.nih.gov/pubmed/30408115
http://dx.doi.org/10.1371/journal.pmed.1002690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224042/
https://www.ncbi.nlm.nih.gov/pubmed/30408115
http://dx.doi.org/10.1371/journal.pmed.1002690

Ejemplares similares